cibinqo
pfizer europe ma eeig - abrocitinib - dermatitis, atópísk - aðrar húðsjúkdómar - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
solifenacin alvogen 5 mg filmuhúðuð tafla (solifenacin portfarma) filmuhúðuð tafla 5 mg
alvogen ehf. - solifenacinum súkkínat - filmuhúðuð tafla - 5 mg
kairasec tafla 8 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 8 mg
kairasec tafla 16 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 16 mg
candpress tafla 16 mg
teva b.v.* - candesartanum cílexetíl - tafla - 16 mg
candpress tafla 8 mg
teva b.v.* - candesartanum cílexetíl - tafla - 8 mg
candpress comp tafla 16 mg/12,5 mg
teva b.v.* - candesartanum cílexetíl; hydrochlorothiazide - tafla - 16 mg/12,5 mg
kairasec tafla 32 mg
medical valley invest ab - candesartanum cílexetíl - tafla - 32 mg
solifenacin alvogen 10 mg filmuhúðuð tafla (solifenacin portfarma) filmuhúðuð tafla 10 mg
alvogen ehf. - solifenacinum súkkínat - filmuhúðuð tafla - 10 mg
entresto
novartis europharm limited - sacubitril, valsartan - hjartabilun - ace ii hemla, önnur sturtu, umboðsmenn starfa á renín-ace kerfi - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.